1. Enhanced antiviral efficacy for valopicitabine (NM283) plus peg-interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial;Afdahl;J. Hepatol.,2005
2. Ahmed, H.A., Alfredson, T.V., Birudaraj, K., Brandl, M.T., Phuapradit, W., Shah, N.H., Stefanidis, D., 2007. HCV prodrug formulation. PCT Int. Appl., WO 2007068615.
3. Alfredson, T., Sarma, K., Brandl, M., Larrabee, S., Wu, X., Tu, Y., Liu, H., Smith, D., Birudaraj, R., Li, F., Tran, T., Hadig, X., Hill, G., Daley, R., Blue, D., Berger, N., Symons, J., Cammack, N., Ipe, D., Berns, H., Lakatos, I., Swallow, S., Klumpp, K., 2006. Design and evaluation of novel HCV polymerase inhibitor prodrugs with enhanced oral bioavailability. AAPS Annual Meeting, San Antonio, TX.
4. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479;Ali;Antimicrob. Agents Chemother.,2008
5. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependant nuclear transcription to antiviral ribonucleosides;Arnold;PLoS Pathog.,2012